Human Endoglin/CD105 Quantikine ELISA Kit

  (22 citations)     
Datasheet / CoA / SDS
Product Details
Assay Procedure
Citations (22)
Supplemental Products
  • Assay Type
    Solid Phase Sandwich ELISA
  • Format
    96-well strip plate
  • Assay Length
    4.5 hours
  • Sample Type & Volume Required Per Well
    Cell Culture Supernates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL)
  • Sensitivity
    0.03 ng/mL
  • Assay Range
    0.2 - 10 ng/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma)
  • Specificity
    Natural and recombinant human Endoglin
  • Cross-reactivity
    < 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
  • Interference
    No significant interference observed with available related molecules.
Control Available
QC23 , Quantikine Immunoassay Control Group 8 - Please Inquire
Product Summary
The Quantikine Human Endoglin Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human Endoglin in cell culture supernates, serum, and plasma. It contains NS0-expressed recombinant human Endoglin and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human Endoglin showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring Endoglin.

Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in forty separate assays to assess inter-assay precision
Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma
Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean 0.617 1.67 3.14 0.659 1.8 3.47
Standard Deviation 0.017 0.053 0.094 0.044 0.117 0.22
CV% 2.8 3.2 3 6.7 6.5 6.3


The recovery of Endoglin spiked to levels throughout the range of the assay was evaluated in cell culture media.

Sample Type Average % Recovery Range %
Cell Culture Media (n=4) 101 92-111
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Endoglin were serially diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
 Endoglin/CD105 [HRP]
Product Datasheets

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Certificate of Analysis Lookup

Certificate of Analysis Request Form

To download a Certificate of Analysis, please enter the catalog and lot numbers in the search box below.

Note: Certificate of Analysis not available for kit components.

Preparation and Storage
  • Storage
    Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Background: Endoglin/CD105
Endoglin (CD105) is a transmembrane type III receptor for TGF-beta superfamily ligands and plays an important role in smooth muscle differentiation, angiogenesis, and neovascularization. It is highly expressed on proliferating vascular endothelial cells, chondrocytes, and syncytiotrophoblasts of term placenta. Human Endoglin haploinsufficiency can a cause the vascular disorder, hereditary hemorrhagic telangiectasia type I. Elevated levels of anti-angiogenic soluble Endoglin contribute to pathogenicity in preeclampsia. Endoglin associates with the receptors TGF-beta RII, Activin RIIA or RIIB, BMPR-IA/ALK-3, or BMPR-IB/ALK6 and enhance binding of Activin A, BMP-2, -7, -9, TGF-beta 1, or TGF-beta 3. Endoglin can either enhance or inhibit signaling through these receptor complexes.
  • Entrez Gene IDs:
    2022 (Human); 13805 (Mouse); 497010 (Rat)
  • Alternate Names:
    CD105 antigen; CD105; Endoglin; ENDOsler-Rendu-Weber syndrome 1; ENG; HHT1FLJ41744; ORW; ORW1
Related Research Areas
Assay Procedure
Refer to the product for complete assay procedure.

Bring all reagents and samples to room temperature before use. It is recommended that all samples, standards, and controls be assayed in duplicate.
  1.   Prepare all reagents, standard dilutions, and samples as directed in the product insert.
  2.   Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.

  3. 100 µL Assay Diluent
  4.   Add 100 µL of Assay Diluent to each well.

  5. 50 µL Standard, Control, or Sample
  6.   Add 50 µL of Standard, control, or sample to each well. Cover with a plate sealer, and incubate at room temperature for 2 hours on a horizontal orbital microplate shaker.
  7.   Aspirate each well and wash, repeating the process 3 times for a total of 4 washes.

  8. 200 µL Conjugate
  9.   Add 200 µL of Conjugate to each well. Cover with a new plate sealer, and incubate at room temperature for 2 hours on the shaker.
  10.   Aspirate and wash 4 times.

  11. 200 µL Substrate Solution
  12.   Add 200 µL Substrate Solution to each well. Incubate at room temperature for 30 minutes on the benchtop. PROTECT FROM LIGHT.

  13. 50 µL Stop Solution
  14.   Add 50 µL of Stop Solution to each well. Read at 450 nm within 30 minutes. Set wavelength correction to 540 nm or 570 nm.

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

22 Citations: Showing 1 - 10
Filter your results:

Sample Type
  1. Lipoprotein apheresis in the treatment of dyslipidaemia - the Czech Republic experience
    Authors: V Bláha, M Bláha, M Lánská, D Solichová, L Kujovská K, E Havel, P Vyroubal, Z Zadák, P Žák, L Sobotka
    Physiol Res, 2017;66(0):S91-S100.
    Species: Human
    Sample Type: Serum
  2. Circulating soluble endoglin modifies the inflammatory response in mice
    Authors: L Ruiz-Remol, C Ollauri-Ib, L Pérez-Roqu, E Núñez-Góme, F Pérez-Barr, JM López-Novo, M Pericacho, A Rodríguez-
    PLoS ONE, 2017;12(11):e0188204.
    Species: Mouse
    Sample Type: Plasma
  3. Endothelial Dysfunction in Severe Preeclampsia is Mediated by Soluble Factors, Rather than Extracellular Vesicles
    Authors: M O'Brien, D Baczyk, JC Kingdom
    Sci Rep, 2017;7(1):5887.
    Species: Human
    Sample Type: Tissue Culture Supernates
  4. Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia
    Authors: Ingrid C Weel
    PLoS ONE, 2016;11(6):e0157584.
    Species: Human
    Sample Type: Tissue Homogenates
  5. High soluble endoglin levels do not induce endothelial dysfunction in mouse aorta.
    Authors: Nemeckova I, Serwadczak A, Oujo B, Jezkova K, Rathouska J, Fikrova P, Varejckova M, Bernabeu C, Lopez-Novoa J, Chlopicki S, Nachtigal P
    PLoS ONE, 2015;10(3):e0119665.
    Species: Mouse
    Sample Type: Plasma
  6. Persistent urinary podocyte loss following preeclampsia may reflect subclinical renal injury.
    Authors: White W, Garrett A, Craici I, Wagner S, Fitz-Gibbon P, Butters K, Brost B, Rose C, Grande J, Garovic V
    PLoS ONE, 2014;9(3):e92693.
    Species: Human
    Sample Type: Serum
  7. MMP-15 Is Upregulated in Preeclampsia, but Does Not Cleave Endoglin to Produce Soluble Endoglin.
    Authors: Kaitu'u-Lino TJ, Palmer K, Tuohey L, Ye L, Tong S
    PLoS ONE, 2012;7(6):e39864.
    Species: Human
    Sample Type: Cell Culture Supernates
  8. Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia.
    Authors: Rana S, Cerdeira A, Wenger J, Salahuddin S, Lim K, Ralston S, Thadhani R, Karumanchi S
    PLoS ONE, 2012;7(10):e48259.
    Species: Human
    Sample Type: Plasma
  9. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
    Authors: Widemann B, Kim A, Fox E, Baruchel S, Adamson P, Ingle A, Glade Bender J, Burke M, Weigel B, Stempak D, Balis F, Blaney S
    Clin Cancer Res, 2012;18(21):6011-22.
    Species: Human
    Sample Type: Plasma
  10. Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer.
    Authors: Landt S, Mordelt K, Schwidde I, Barinoff J, Korlach S, Stoblen F, Lichtenegger W, Sehouli J, Kummel S
    Anticancer Res., 2011;31(8):2651-5.
    Species: Human
    Sample Type: Serum
  11. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
    Authors: Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM
    Clin. Cancer Res., 2011;17(15):5113-22.
    Species: Human
    Sample Type: Plasma
  12. Circulating soluble endoglin levels in pregnant women in Cameroon and Malawi--associations with placental malaria and fetal growth restriction.
    Authors: Silver KL, Conroy AL, Leke RG, Leke RJ, Gwanmesia P, Molyneux ME, Wallace DT, Rogerson SJ, Kain KC
    PLoS ONE, 2011;6(9):e24985.
    Species: Human
    Sample Type: Plasma
  13. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
    Authors: Powers RW, Jeyabalan A, Clifton RG
    PLoS ONE, 2010;5(10):e13263.
    Species: Human
    Sample Type: Serum
  14. Effect of smoking on circulating angiogenic factors in high risk pregnancies.
    Authors: Jeyabalan A, Powers RW, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M, Caritis S, Roberts JM, Kuller J, Cotroneo M, Kamon T, Mercer B, Ramsey R, Paul R, Rabello Y, McCart D, Mueller E, Goldenberg R, Copper R, Sorokin Y, Norman G, Millinder A, Christmas JT, McCoy S, Elder S, Elder N, Carter B, Pemberton V, Thurnau G, Meier A, Minton V, Meis P, Swain M, Moawad AH, Jones P, Iams JD, Meadows S, Brenner S, Collins B, Newman RB, Carter SG, Romero R, Sabo V, Thom E, Bain RP, MacPherson C, Johnson D, Fischer ML, McNellis D, Spong C, Catz C, Yaffe S
    PLoS ONE, 2010;5(10):e13270.
    Species: Human
    Sample Type: Serum
  15. Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia.
    Authors: Santner-Nanan B, Peek MJ, Khanam R, Richarts L, Zhu E, Fazekas de St Groth B, Nanan R
    J. Immunol., 2009;183(11):7023-30.
    Species: Human
    Sample Type: Serum
  16. A proof-of-principle gel-free proteomics strategy for the identification of predictive biomarkers for the onset of pre-eclampsia.
    Authors: Blankley RT, Gaskell SJ, Whetton AD
    BJOG, 2009;116(11):1473-80.
    Species: Human
    Sample Type: Plasma
  17. Soluble endoglin modulates aberrant cerebral vascular remodeling.
    Authors: Chen Y, Hao Q, Kim H, Su H, Letarte M, Karumanchi SA, Lawton MT, Barbaro NM, Yang GY, Young WL
    Ann. Neurol., 2009;66(1):19-27.
    Species: Human
    Sample Type: Tissue Homogenates
  18. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer.
    Authors: Karam JA, Svatek RS, Karakiewicz PI, Gallina A, Roehrborn CG, Slawin KM, Shariat SF
    Clin. Cancer Res., 2008;14(5):1418-22.
    Species: Human
    Sample Type: Plasma
  19. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy.
    Authors: Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF
    Clin. Cancer Res., 2008;14(11):3362-6.
    Species: Human
    Sample Type: Plasma
  20. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
    Authors: Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, Saad F, Slawin KM, Karakiewicz PI
    Clin. Cancer Res., 2008;14(12):3785-91.
    Species: Human
    Sample Type: Plasma
  21. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Authors: Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA
    N. Engl. J. Med., 2006;355(10):992-1005.
    Species: Human
    Sample Type: Serum
  22. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer.
    Authors: Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, Boneberg EM
    Br. J. Cancer, 2006;94(4):524-31.
    Species: Human
    Sample Type: Serum
Expand to show all Citations


No product specific FAQs exist for this product, however you may

View all ELISA FAQs
ELISA Controls
Description Application Cat# Citations Images  

Quantikine Immunoassay Control Group 8

Ctrl QC23  
View Sizes & Prices
Catalog# Size Price Stock Quantity
Loading Information....
Supplemental ELISA Products
Description Application Cat# Citations Images  

Quantikine ELISA Wash Buffer 1

ELISA WA126 6  
View Sizes & Prices
Catalog# Size Price Stock Quantity
Loading Information....

Have you used Human Endoglin/CD105 Quantikine ELISA Kit?

Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

Order Details

Contact Us to Order


Customer Information
Associated Pathways
R&D Systems Guarantee